NovoCure (NASDAQ:NVCR) CEO Sells $74,629.17 in Stock

NovoCure Limited (NASDAQ:NVCR) CEO Frank Leonard sold 5,607 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $13.31, for a total transaction of $74,629.17. Following the sale, the chief executive officer owned 493,793 shares of the company’s stock, valued at $6,572,384.83. This trade represents a 1.12% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link.

NovoCure Stock Performance

NVCR opened at $13.04 on Friday. NovoCure Limited has a 1-year low of $9.82 and a 1-year high of $21.55. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -10.69 and a beta of 0.71. The company’s fifty day moving average price is $12.74 and its two-hundred day moving average price is $12.72. The company has a current ratio of 2.90, a quick ratio of 1.50 and a debt-to-equity ratio of 0.70.

NovoCure (NASDAQ:NVCR) last issued its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.19. The firm had revenue of $174.35 million during the quarter, compared to analysts’ expectations of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The business’s revenue was up 8.2% on a year-over-year basis. During the same period last year, the company earned ($0.61) earnings per share. On average, analysts expect that NovoCure Limited will post -1.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the company. Empowered Funds LLC purchased a new position in NovoCure during the fourth quarter worth about $33,000. SJS Investment Consulting Inc. purchased a new stake in NovoCure in the 3rd quarter valued at about $41,000. Kestra Advisory Services LLC bought a new position in shares of NovoCure during the 4th quarter worth approximately $49,000. Larson Financial Group LLC lifted its position in shares of NovoCure by 662.1% during the 3rd quarter. Larson Financial Group LLC now owns 4,100 shares of the medical equipment provider’s stock worth $53,000 after buying an additional 3,562 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of NovoCure by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,442 shares of the medical equipment provider’s stock worth $70,000 after buying an additional 1,120 shares during the last quarter. 84.61% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on NVCR shares. HC Wainwright lifted their price target on NovoCure from $47.00 to $49.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of NovoCure in a research note on Thursday, January 22nd. Evercore set a $20.00 target price on NovoCure in a report on Monday, January 5th. Finally, Wedbush reaffirmed a “neutral” rating and set a $18.00 target price on shares of NovoCure in a research report on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, NovoCure presently has an average rating of “Hold” and a consensus target price of $26.93.

Key Stories Impacting NovoCure

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year‑over‑year — a fundamental positive that supports a recovery narrative and gives analysts a basis for higher targets. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive (e.g., HC Wainwright raised its target and several analysts maintain Buy ratings), providing upside scenarios if clinical/commercial momentum continues. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerage consensus is an overall “Hold,” signaling limited near‑term conviction for a sustained re‑rating despite divergent analyst targets. NovoCure receives average “Hold” rating
• Neutral Sentiment: High institutional ownership (~84.6%) concentrates share control; that reduces free float but means large insider blocks can have outsized market impact when sold. Institutional holdings (MarketBeat)
• Neutral Sentiment: Minor individual insider sale by Michal Nath Puri (1,100 shares) is immaterial alone but contributes to the overall recent selling narrative. InsiderTrades alert
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k), trimming his stake by ~18% — a substantial single insider sale that markets typically read as negative signaling. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same window — an aggregated pattern that likely amplified selling pressure and contributed to intraday weakness. SEC filings: Executive sales summary

NovoCure Company Profile

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.